This educational program aims to prepare family physicians and APPs to navigate the expanding role of PCSK9 inhibitors beyond secondary prevention and into selected high-risk primary prevention populations. Through review of emerging clinical evidence, guideline evolution, and practical patient-selection strategies, our expert faculty will help learners identify which patients without established ASCVD may benefit from earlier, more intensive LDL-C lowering while integrating cardiovascular risk, comorbidities, and prior lipid-lowering therapy into individualized treatment decisions. The program also emphasizes practical collaboration between primary care clinicians and cardiovascular or lipid specialists to support coordinated referral pathways, shared-care models, and long-term adherence for patients who may be candidates for PCSK9 inhibitor therapy.
Family physicians and their care teams, including APPs, nurses, and pharmacists, as well as other primary care-focused HCPs who contribute to the management of patients with a high burden of ASCVD risk
Describe the evolving evidence base for PCSK9 inhibition, including key secondary prevention trials and new primary prevention data, and explain how this evidence supports earlier, more intensive LDL-C lowering in selected high-risk patients without prior ASCVD events
Identify primary prevention patients in family medicine who may benefit from PCSK9 inhibitor therapy by integrating global cardiovascular risk, LDL-C thresholds, prior lipid-lowering therapy, comorbidities, and current guideline recommendations into individualized treatment decisions
Outline practical strategies for effective communication and collaboration between family physicians, APPs, and cardiovascular/lipid specialists to co-manage high-risk patients who are candidates for PCSK9 inhibitors in both secondary and primary prevention, including clear referral criteria, shared-care plans, and coordinated follow-up to optimize outcomes and adherence
Introductions and Framing the Gap - Alan S. Brown, MD
Evidence Base for PCSK9 Inhibition: From Secondary to Primary Prevention - Alan S. Brown, MD
Identifying the Right Patients in Family Medicine - Alan S. Brown, MD
Collaboration with Specialists: Operationalizing Shared Care - Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert
Faculty Panel and Summary - Alan S. Brown, MD & Viet Le, DMSc, MPAS, PA-C, FACC FAHA, HF-Cert
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Alan S. Brown, MD, MHA FACC, FAHA, MNLA
|
Consultant/Advisor: Amgen; Arrowhead Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; Merck & Co., Inc.; NewAmsterdam Pharma; Novartis AG
Speaker's Bureau: Amgen; Arrowhead Pharmaceuticals, Inc.; Regeneron Pharmaceuticals Inc. |
| Viet Le, DMSc, MPAS, PA-C, FACC
|
Consultant/Advisor: Amgen; Bayer AG; Esperion Therapeutics, Inc.; Idorsia Pharmaceuticals Ltd; iRhythm Technologirs, Inc.; Novartis AG; Novo Nordisk; Merck & Co., Inc.
Grant/Research Support: AliveCor, Inc.; Johnson & Johnson |
Timothy Hayes, MD, PhD; Kim Cheramie, PhD, MSN, RN, NPDA-BC; Chelsey Simonds and Nicole McMenamin hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 1.25 CNE Contact Hours, including 1.25 pharmacotherapeutic contact hours (Provider number P0491).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Amgen.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
